Stock listing
Munich:0JZ Carvolix Aktie
German listing (Munich) of Carvolix · home listing Euronext:CVX
Follow Carvolix into a list and get an email when it puts out news.
Home listing price · EURONEXT:CVX
€4.29 EUR -0.38 (-8.1%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, EURONEXT:CVX
- Day range
- €4.20 – €4.66 EURNov 20, 2026
- Volume
- 47,082 sharesNov 20, 2026
- Market cap
- €267.0M EURAt the close on Nov 20, 2026 · price × 62.23M shares outstanding
- 52-week range
- €1.33 – €7.56 EURLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- €152,430 EURMedian day 15,652 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| Euronext:CVX · Home | €4.29 EUR | -0.38 (-8.1%) | 47,082 | €4.30 | €4.66 | €4.20 | €4.67 | Close on Nov 20, 2026 |
| Frankfurt:0JZ | €4.44 EUR | -0.13 (-2.8%) | — | €4.43 | €4.50 | €4.43 | €4.57 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · EURONEXT:CVX · EUR, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| €4.29 | -0.38 | -8.1% | €4.30 | €4.66 | €4.20 | 47,082 | |
| €4.67 | +0.07 | +1.5% | €4.60 | €4.74 | €4.60 | 6,730 | |
| €4.60 | -0.20 | -4.2% | €4.81 | €4.81 | €4.57 | 12,791 | |
| €4.80 | -0.05 | -1.0% | €4.82 | €4.93 | €4.70 | 19,415 | |
| €4.85 | -0.09 | -1.8% | €5.10 | €5.10 | €4.85 | 12,558 | |
| €4.94 | -0.10 | -2.0% | €5.10 | €5.10 | €4.88 | 16,786 | |
| €5.04 | 0.00 | 0.0% | €5.04 | €5.08 | €4.85 | 35,839 | |
| €5.04 | +0.12 | +2.4% | €4.92 | €5.24 | €4.92 | 28,140 | |
| €4.92 | +0.02 | +0.4% | €4.91 | €5.08 | €4.88 | 13,903 | |
| €4.90 | -0.05 | -1.0% | €4.92 | €5.02 | €4.84 | 23,570 | |
| €4.95 | -0.33 | -6.3% | €5.32 | €5.34 | €4.87 | 53,317 | |
| €5.28 | -0.04 | -0.8% | €5.42 | €5.46 | €5.26 | 8,221 | |
| €5.32 | -0.16 | -2.9% | €5.46 | €5.50 | €5.32 | 15,565 | |
| €5.48 | -0.18 | -3.2% | €5.68 | €5.68 | €5.48 | 14,055 | |
| €5.66 | -0.10 | -1.7% | €5.78 | €5.78 | €5.60 | 7,998 | |
| €5.76 | +0.22 | +4.0% | €5.56 | €5.80 | €5.46 | 11,525 | |
| €5.54 | +0.02 | +0.4% | €5.60 | €5.64 | €5.48 | 13,245 | |
| €5.52 | -0.36 | -6.1% | €5.88 | €5.90 | €5.36 | 40,218 | |
| €5.88 | +0.10 | +1.7% | €5.80 | €6.08 | €5.76 | 29,181 | |
| €5.78 | -0.16 | -2.7% | €5.94 | €5.94 | €5.76 | 6,634 | |
| €5.94 | +0.02 | +0.3% | €5.96 | €5.96 | €5.76 | 15,136 | |
| €5.92 | +0.16 | +2.8% | €5.78 | €5.92 | €5.66 | 24,320 | |
| €5.76 | -0.24 | -4.0% | €5.88 | €5.88 | €5.52 | 16,950 | |
| €6.00 | +0.74 | +14.1% | €5.16 | €6.00 | €4.92 | 67,293 | |
| €5.26 | +0.10 | +1.9% | €5.20 | €5.34 | €5.12 | 14,630 | |
| €5.16 | -0.02 | -0.4% | €5.24 | €5.24 | €5.08 | 6,643 | |
| €5.18 | -0.04 | -0.8% | €5.22 | €5.22 | €5.14 | 11,515 | |
| €5.22 | -0.08 | -1.5% | €5.26 | €5.26 | €5.04 | 21,540 | |
| €5.30 | -0.08 | -1.5% | €5.38 | €5.42 | €5.28 | 10,832 | |
| €5.38 | +0.12 | +2.3% | €5.58 | €5.58 | €5.28 | 11,271 | |
| €5.26 | -0.42 | -7.4% | €5.66 | €5.72 | €5.22 | 24,788 | |
| €5.68 | -0.10 | -1.7% | €5.78 | €5.80 | €5.60 | 9,490 | |
| €5.78 | +0.14 | +2.5% | €5.68 | €5.80 | €5.66 | 6,521 | |
| €5.64 | -0.14 | -2.4% | €5.80 | €5.80 | €5.56 | 11,912 | |
| €5.78 | +0.04 | +0.7% | €5.76 | €5.86 | €5.70 | 31,127 | |
| €5.74 | -0.04 | -0.7% | €5.80 | €5.86 | €5.70 | 28,114 | |
| €5.78 | +0.24 | +4.3% | €5.74 | €5.82 | €5.54 | 20,707 | |
| €5.54 | +0.02 | +0.4% | €5.52 | €5.80 | €5.48 | 22,070 | |
| €5.52 | -0.12 | -2.1% | €5.68 | €5.68 | €5.48 | 12,884 | |
| €5.64 | -0.06 | -1.1% | €5.76 | €5.76 | €5.60 | 8,195 | |
| €5.70 | -0.12 | -2.1% | €5.84 | €5.84 | €5.70 | 9,644 | |
| €5.82 | +0.16 | +2.8% | €5.82 | €5.92 | €5.76 | 30,555 | |
| €5.66 | -0.04 | -0.7% | €5.70 | €5.70 | €5.60 | 13,344 | |
| €5.70 | 0.00 | 0.0% | €5.74 | €5.76 | €5.64 | 12,976 | |
| €5.70 | -0.08 | -1.4% | €5.88 | €5.88 | €5.70 | 7,537 | |
| €5.78 | -0.10 | -1.7% | €5.90 | €5.90 | €5.74 | 9,730 | |
| €5.88 | +0.08 | +1.4% | €5.80 | €5.90 | €5.78 | 5,504 | |
| €5.80 | -0.06 | -1.0% | €5.88 | €5.88 | €5.72 | 15,739 | |
| €5.86 | -0.02 | -0.3% | €5.90 | €5.96 | €5.84 | 9,965 | |
| €5.88 | +0.02 | +0.3% | €5.96 | €5.96 | €5.82 | 7,495 | |
| €5.86 | +0.22 | +3.9% | €6.00 | €6.16 | €5.82 | 33,285 | |
| €5.64 | -0.16 | -2.8% | €5.78 | €5.80 | €5.52 | 35,964 | |
| €5.80 | +0.10 | +1.8% | €5.76 | €5.86 | €5.76 | 12,475 | |
| €5.70 | 0.00 | 0.0% | €5.70 | €5.70 | €5.70 | 21,816 | |
| €5.70 | -0.42 | -6.9% | €6.26 | €6.26 | €5.66 | 91,388 | |
| €6.12 | +0.16 | +2.7% | €6.04 | €6.16 | €5.96 | 11,968 | |
| €5.96 | -0.22 | -3.6% | €6.18 | €6.20 | €5.94 | 19,749 | |
| €6.18 | -0.10 | -1.6% | €6.28 | €6.44 | €6.16 | 30,698 | |
| €6.28 | -0.12 | -1.9% | €6.40 | €6.48 | €6.22 | 17,244 | |
| €6.40 | -0.18 | -2.7% | €6.58 | €6.60 | €6.32 | 41,217 | |
| €6.58 | +0.08 | +1.2% | €6.52 | €6.72 | €6.44 | 28,953 | |
| €6.50 | -0.68 | -9.5% | €7.08 | €7.10 | €6.50 | 107,906 | |
| €7.18 | +1.06 | +17.3% | €6.66 | €7.32 | €6.44 | 274,972 | |
| €6.12 | +0.06 | +1.0% | €6.06 | €6.22 | €6.02 | 29,922 | |
| €6.06 | +0.04 | +0.7% | €6.12 | €6.28 | €6.02 | 11,152 | |
| €6.02 | -0.12 | -2.0% | €6.10 | €6.22 | €6.00 | 20,188 |
- Ticker
- Munich:0JZ
- Asset type
- Stock
- Sector
- Health care
- Industry
- Medical devices & supplies
- Exchange
- Munich
- Currency
- EUR
What changed lately
Latest news release · Nov 4, 2026
Nombre d’actions composant le capital social et nombre total de droits de vote au 31.10.26.
Latest deck · Sep 16, 2026
Investor Presentation (September 2026)
Investor deck · 23 slides
Latest news
Nombre d’actions composant le capital social et nombre total de droits de vote au 31.10.26.
Nov 4, 2026
Closed €5.28 (-0.8%) on Nov 4, 2026
Nombre d’actions composant le capital social et nombre total de droits de vote au 30.09.26
Oct 8, 2026
Closed €5.26 (-7.4%) on Oct 8, 2026
Carvolix Appoints Anne Lange as Chair of its Board of Directors Confirming the Acceleration of its Ambitions and Reports 2026 Half-Year Results.
Sep 30, 2026
Closed €5.74 (-0.7%) on Oct 1, 2026
Carvolix nomme Anne Lange à la présidence de son Conseil d'administration et publie ses résultats semestriels 2026, confirmant l'accélération de ses ambitions.
Sep 30, 2026
Closed €5.78 (+4.3%) on Sep 30, 2026
Carvolix submits 510(k) for TAVIPILOT Robot, advancing toward US commercial launch of Its Integrated TAVIPILOT Platform.
Sep 22, 2026
Closed €5.82 (+2.8%) on Sep 23, 2026
Carvolix Takes a Key Step Toward Commercial Launch of TAVIPILOT Software in Europe with Regulatory Submission for CE Marking.
Sep 9, 2026
Closed €5.86 (+3.9%) on Sep 10, 2026
Carvolix Secures EUR 30 Million Of Structured Debt Financing To Fuel Its Growth.
Aug 6, 2026
Closed €6.32 (+6.4%) on Aug 6, 2026
Carvolix: ODDO BHF initiates coverage of Carvolix with an Outperform rating.
Jul 29, 2026
Closed €6.86 (+12.5%) on Jul 30, 2026
Carvolix presents promising clinical data on the TAVIPILOT platform at New York Valves 2026
Jul 6, 2026
Closed €4.40 (+10.0%) on Jul 6, 2026
Carvolix Secures New EUR 10m Tranche, Bringing Total Financing to EUR 20m as Part of its EUR 30m Programme
Jun 24, 2026
Closed €3.40 (-3.7%) on Jun 24, 2026
Carvolix on 6ix
- Sector
- Health care
- Industry
- Medical devices & supplies
- News releases
- 19 in the last 12 months · 19 in all · newest Nov 4, 2026 · oldest 2025
- Decks
- 3 decks · latest Sep 16, 2026
Where Carvolix is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| Euronext:CVX · Home listing | Euronext | France | EUR |
| gettex:0JZ | gettex | Germany | EUR |
| LS Exchange:A3CRZT | LS Exchange | Germany | EUR |
| Lang & Schwarz:A3CRZT | Lang & Schwarz | Germany | EUR |
| Aquis:CVXP | Aquis | United Kingdom | EUR |
| Aquis:CVXP | Aquis | United Kingdom | EUR |
| Frankfurt:0JZ | Frankfurt | Germany | EUR |
| Munich:0JZ · This page | Munich | Germany | EUR |
| Stuttgart:0JZ | Stuttgart | Germany | EUR |
Valuation
Price/book 6.2× against a median of 3.3×: 8th lowest of 11 Medical devices & supplies companies shown. Statements: Year to Dec 31, 2025 · balance Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- €279.4M EUR
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 6.2×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.5×
- Beta
- No index for this market yet
Medical devices & supplies: the 10 companies nearest in size, of 448 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Carvolix · EURONEXT:CVX | US$293.0M | US$306.6M | n/a | n/a | n/a | 6.2× | n/a | 0.5× | n/a |
| CapsoVision, Inc. · NASDAQ:CV | US$325.1M | US$304.1M | n/a | 21.9× | n/a | 12.3× | −210.1% | 0.0× | 0.88 |
| NIOX Group PLC · LSE:NIOX | US$318.1M | US$297.0M | 34.7× | 4.7× | 15.3× | 3.7× | 14.4% | 0.0× | n/a |
| Nanjing Medlander Medical Technology Co. Ltd. Class A · SSE:688273 | US$315.5M | US$208.7M | 33.0× | 3.6× | n/a | 1.5× | 16.6% | 0.0× | n/a |
| Supermax Corp. Bhd. · MYX:SUPERMX | US$312.4M | US$215.6M | n/a | 1.2× | n/a | 0.3× | −20.9% | 0.1× | n/a |
| Chongqing Xishan Science and Technology Co., Ltd. Class A · SSE:688576 | US$301.5M | US$216.0M | n/a | 5.2× | n/a | 1.2× | −19.2% | 0.0× | n/a |
| Sanara MedTech Inc. · NASDAQ:SMTI | US$299.1M | US$329.0M | n/a | 2.9× | 34.4× | 39.0× | −2.7% | 6.1× | 0.49 |
| Peijia Medical Ltd. · HKEX:9996 | US$297.8M | US$280.7M | n/a | 2.6× | n/a | 1.1× | −28.5% | 0.3× | n/a |
| Jiangsu Apon Medical Technology Co. Ltd. Class A · SZSE:300753 | US$293.3M | US$281.1M | n/a | 5.8× | n/a | 3.0× | −9.1% | 0.0× | n/a |
| Treace Medical Concepts, Inc. · NASDAQ:TMCI | US$282.6M | US$302.8M | n/a | 1.5× | n/a | 4.6× | −27.4% | 1.0× | 2.03 |
| NeuroPace, Inc. · NASDAQ:NPCE | US$273.9M | US$283.8M | n/a | 2.8× | n/a | 23.8× | −18.4% | 5.2× | 1.23 |
| Median of the others | US$300.3M | US$282.4M | 33.9× | 3.3× | 24.9× | 3.3× | −18.8% | 0.1× | 1.06 |
Forecasts
Analysts' consensus from EODHD, read Nov 11, 2026. Not 6ix's view and not investment advice.
- Price target
- 8.78 EUR · Analysts' mean
- EPS, year to Dec 2026
- -0.48 · 2 analysts
- Revenue, year to Dec 2026
- 1.43M · 4 analysts
Team and board
| Director | Role |
|---|---|
| Anne Lange | Chair of the Board of Directors |
| Michel Therin | Vice-Chair of the Board |
| Rute Fernandes | Director |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (September 2026) | Investor deck | 23 slides | Sep 16, 2026 |
| Affluent Medical — IPO Roadshow (May 2021) | IPO roadshow | 49 slides | May 27, 2021 |
| Affluent Medical — IPO Roadshow (May 2021) | IPO roadshow | 49 slides | May 2021 |
Financings
| Raise | Date | In US dollars |
|---|---|---|
| Senior secured convertible bonds, amortised bonds and warrants Announced: up to €30M · Warrants at €3.96 for 120 months Buyers: Claret Capital Partners (lender; first tranche of EUR 10,000,000 convertible bonds drawn, up to EUR 30 million in total, plus 290,937 warrants issued to CEGCF IV Aggregator L.P. (a Claret entity)) Use of proceeds: US commercialization of the TAVIPILOT Robotic System and development of Kalios, Artus, Artedrone and Mitrapilot | Aug 6, 2026 | US$34.59M |
| Private placement of new ordinary shares Announced: €10M · €3.36 a share Buyers: Edwards Lifesciences (EUR 5 million (1,488,095 New Shares)); funds managed by Truffle Capital (EUR 5 million (1,488,095 New Shares)) Insiders: Funds managed by Truffle Capital subscribed EUR 5 million; directors affiliated with Truffle Capital did not participate in the board deliberations Use of proceeds: Product development (Tavipilot, Kalios, Artus, Artedrone, Mitrapilot) and EUR 2.5 million to repay a Truffle Capital bridge financing | Jun 24, 2026 | US$11.35M |
| Private placement of new ordinary shares Tranche closed: €10.3M raised · €2.34 a share Buyers: Edwards Lifesciences (2,136,752 new shares; 9.7% ownership post-round); Truffle Medeor FPCI (€1.5M in the first tranche at €2.34 per share); Truffle BioMedTech Crossover FPCI (€3.5M in the first tranche at €2.34 per share); Truffle BioMedTech Crossover; Truffle Innov FRR; Truffle Medeor; Financière Memnon; HAYK Holding Sàrl; Ginko Invest; Simone Merkle; Edwards Lifesciences Holding, Inc.; Truffle Capital (funds managed by Truffle Capital; 2,136,751 new shares) Insiders: Truffle Capital funds (related party; Dr. Philippe Pouletty, Truffle representative and director, abstained) commit €1.5M and €3.5M in the first tranche Use of proceeds: Extend cash runway to end of May 2026; clinical and regulatory development of TAVIpilot, Artus, Kalios, Epygon and ARTE-DRONE | Feb 2, 2026 | US$12.15M |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in EUR
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 4.12M | 0 | 0 | 0 | 0 |
| Cost of revenue | 13.4M | 2.42M | 2.44M | 2.74M | ||
| Gross profit | -9.27M | -1.20M | -1.10M | -1.29M | ||
| Research and development | 94.0K | 72.0K | 52.0K | 23.0K | ||
| Selling, general and administrative | 13.7M | 11.8M | 5.16M | 5.19M | ||
| Operating income | -23.7M | -14.6M | -15.4M | -14.3M | -13.2M | -13.0M |
| Depreciation and amortization | 6.63M | 2.40M | 2.41M | 2.45M | 2.42M | 1.91M |
| EBITDA | -17.1M | -12.2M | -13.0M | -11.8M | -10.8M | -11.1M |
| Interest expense | 242.0K | 393.0K | 1.08M | 3.06M | ||
| Income before tax | -25.1M | -14.9M | -15.8M | -15.4M | -15.3M | -14.5M |
| Income tax | -123.0K | -142.0K | -150.0K | -173.0K | -437.0K | -209.0K |
| Net income | -25.0M | -14.7M | -15.7M | -15.2M | -14.8M | -14.3M |
| Earnings per share, basic | -0.63 | -0.41 | -0.54 | -0.81 | -0.88 | -1.07 |
| Earnings per share, diluted | -0.63 | -0.41 | -0.54 | -0.81 | -0.88 | -1.07 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | 1.75M | 1.23M | 1.66M | 2.58M | 11.4M | 5.65M |
| Short-term investments | 5.39M | |||||
| Receivables | 3.45M | 3.40M | 4.05M | 2.89M | ||
| Current assets | 7.10M | 12.2M | 5.79M | 7.18M | 14.7M | 7.91M |
| Goodwill | 26.8M | 32.2M | 32.2M | 32.2M | 32.2M | 32.2M |
| Total assets | 48.0M | 60.9M | 56.7M | 60.0M | 70.0M | 64.8M |
| Accounts payable | 6.08M | 4.73M | 3.37M | 3.02M | 1.79M | 2.35M |
| Current liabilities | 23.5M | 9.53M | 8.42M | 8.64M | 7.30M | 9.77M |
| Long-term debt | 11.9M | 14.1M | 14.4M | 14.9M | 16.1M | 16.2M |
| Total debt | 22.9M | 15.5M | 16.2M | 16.6M | 18.5M | 19.8M |
| Total liabilities | 30.6M | 25.2M | 26.2M | 26.5M | ||
| Shareholders' equity | 5.76M | 30.3M | 31.5M | 33.8M | 43.5M | 35.3M |
| Shares outstanding | 39.3M | 39.3M | 30.9M | 20.8M | 18.2M | 15.3M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash from operations | -11.6M | -11.3M | -12.1M | -11.1M | -12.4M | -8.94M |
| Capital spending | -116.0K | -147.0K | -171.0K | -146.0K | -334.0K | -304.0K |
| Free cash flow | -11.7M | -11.5M | -12.2M | -11.2M | -12.7M | -9.24M |
| Cash from investing | 5.25M | -480.0K | -184.0K | -146.0K | -160.0K | -304.0K |
| Cash from financing | 6.83M | 11.4M | 11.3M | 2.40M | 18.3M | 12.8M |
| Change in cash | 524.0K | -434.0K | -922.0K | -8.83M | 5.76M | 3.52M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| Carvolix : Nombre d’actions composant le capital social et nombre total de droits de vote au 31.10.26. | Nov 4, 2026 | Other filings | Euronext |
| Carvolix : Nombre d’actions composant le capital social et nombre total de droits de vote au 30.09.26 | Oct 8, 2026 | Other filings | Euronext |
| Carvolix Appoints Anne Lange as Chair of its Board of Directors Confirming the Acceleration of its Ambitions and Reports 2026 Half-Year Results. | Sep 30, 2026 | Results | Euronext |
| Carvolix nomme Anne Lange à la présidence de son Conseil d'administration et publie ses résultats semestriels 2026, confirmant l'accélération de ses ambitions. | Sep 30, 2026 | Other filings | Euronext |
Cap table
Built by 6ix from Carvolix’s releases · as of Aug 6, 2026
- Common shares
- 62,228,152
- Fully diluted
- 62,228,152
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 62,228,152 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 62,228,152 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Anne Lange | Chair of the Board of Directors · Since Apr 9, 2026 |
| Liane Teplitsky | Chair of the Board of Directors of Carvolix, , · Since at least Apr 9, 2026 |
| Michel Therin | Vice-Chair of the Board · Since Apr 9, 2026 |
| Rute Fernandes | Director · Since at least Apr 9, 2026 |
| Soad El Gazaoui | Until Apr 9, 2026 · Past |
Log in to ask 6ix AI your own questions about Carvolix.